[Experiences with Wy 4036, a new tranquilizing agent from the benzodiazepine group].
D000275:Adjustment Disorders / Q000188:drug therapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D001007:Anxiety / Q000188:drug therapy; D001552:Benzazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001930:Brain Injuries / Q000188:drug therapy; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy; D003865:Major Depressive Disorder / Q000188:drug therapy; D004402:Dysautonomia, Familial / Q000188:drug therapy; D005260:Female; D006801:Humans; D002537:Intracranial Arteriosclerosis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy; D009497:Neurotic Disorders / Q000188:drug therapy; D012893:Sleep Wake Disorders / Q000188:drug therapy; D014149:Tranquilizing Agents / Q000627:therapeutic use
D001552:Benzazepines; D014149:Tranquilizing Agents
Erfahrungen mit Wy 4036, einem neuen Tranquilizer aus der Benzodiazepin-Reihe.